Abstract

A structure, method, and computer program product for a diabetes control system provides, but is not limited thereto, the following: open-loop or closed-loop control of diabetes that adapts to individual physiologic characteristics and to the behavioral profile of each person. An exemplary aspect to this adaptation is biosystem (patient or subject) observation and modular control. Consequently, established is the fundamental architecture and the principal components for a modular system, which may include algorithmic observers of patients' behavior and metabolic state, as well as interacting control modules responsible for basal rate, insulin boluses, and hypoglycemia prevention.

IPC Classes  ?

• G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
• A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
• A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration, pH-value
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders

Abstract

Methods of modeling the in vivo efficacy of drug combinations for the treatment or prevention of viral infection are described. The described methods combine data for single drugs and drug combinations from pharmacokinetic, pharmacodynamic, and viral dynamics models under a series of estimated in vivo drug potencies to provide predictions of the in vivo effects of the drug combinations. These predictions can be used to more accurately select drugs and drug treatment regimens that can be successful in controlling viral infection in animal studies, clinical trials and in medical or veterinary interventions. Also described is a method of treating or preventing filovirus infections using combinations of orally available drugs based on predictions from the modeling methods.

IPC Classes  ?

• G16H 70/40 - ICT specially adapted for the handling or processing of medical references relating to drugs, e.g. their side effects or intended usage
• A61K 31/138 - Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
• A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 31/14 - Antivirals for RNA viruses
• G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders

Abstract

Provided are compositions that include targeting peptides and methods for using the same to treat and/or prevent various diseases, disorders, and/or conditions. In some embodiments, the compositions and methods relate to liposomal compositions that include a liposome, the surface of which is conjugated to a peptide having an amino acid sequence as set forth in any of SEQ ID NOS: 3-38, optionally wherein the liposome encapsulates a therapeutic agent or a detectable agent. In some embodiments, the peptide has an amino acid sequence that is one of SEQ ID NOs: 14, 19, 20, 27, and 28. Also provided are methods treating or preventing fibrosis, for decreasing the incidence of a disease, disorder, or condition associated with chronic pancreatitis (CP), for targeting active agents to targets, including but not limited to collagen III-expressing cells and extracellular matrix, and for decreasing incidence of side effects associated with apigenin treatment.

IPC Classes  ?

• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 47/58 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
• A61P 5/00 - Drugs for disorders of the endocrine system
• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids

Abstract

Disclosed are compositions and methods for treating a disease or disorder such as cancer in a subject in need thereof. In some aspects, the method comprises administering to the subject a vector comprising a first nucleic acid sequence encoding a promoter operably linked to each of a second nucleic acid sequence encoding a therapeutic polypeptide, and a third nucleic acid sequence encoding a peptide domain that is stabilized when phosphorylated by kinase activity in a target tissue. The kinase activity can be elevated extracellular regulated kinase (ERK) activity.

IPC Classes  ?

• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• A61P 35/00 - Antineoplastic agents
• C07K 14/035 - Herpes simplex virus I or II
• C07K 14/39 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
• C12N 15/86 - Viral vectors

Abstract

Embodiments relate to a dynamic spectrum access (DSA) system including a DSA transmitter configured to generate a complex signal for a secondary communication system, the complex signal being within a communication band A that is equal to or falls within a communication band B of a primary communication system. The complex signal includes a first signal and a second signal that is a repeat of the first signal. The power of the complex signal received at the secondary communication receiver is greater than the noise floor of the secondary communication system, but is equal to or less than the interference power from the primary communication. The DSA system includes a DSA receiver including a plurality of DSA antennas and a DSA signal processing module, the DSA signal processing module configured to perform canonical correlation analysis (CCA) on the complex signal.

IPC Classes  ?

• H04W 16/14 - Spectrum sharing arrangements

Abstract

Provided herein is a previously unannotated IncRNA lying within exon six and 3′UTR of the LCK gene, labeled “HULLK” for Hormone-Upregulated IncRNA within LCK. HULLK is a novel IncRNA situated within the LCK gene that can serve as an oncogene in PCa. Accordingly, provided are methods and compositions for diagnosing and treating prostate cancer based on HULLK that regulates prostate cancer cell growth.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

It is disclosed herein that RPE degeneration in human cell culture and in mouse models is driven by a non-canonical inflammasome pathway that results in activation of caspase-4 (also known as caspase-11 in mouse) and caspase-1, and requires cyclic GMP-AMP synthase (cGAS)-dependent interferon-β (IFN-β) production and gasdermin D-dependent interleukin-18 (IL-18) secretion. Reduction of DICER1 or accumulation of Alu RNA triggers cytosolic escape of mitochondrial DNA, which engages cGAS. Collectively, these data highlight an unexpected role for cGAS in responding to mobile element transcripts, reveal cGAS-driven interferon signaling as a conduit for mitochondrial damage-induced NLRP3 activation, and expand the immune sensing repertoire of cGAS and caspase-4 to non-infectious human disease. Coupled with the unexpected result that caspase-4, gasdermin D, IFN-β, and cGAS are elevated in the RPE of human eyes with geographic atrophy, these findings also identify new targets for a major cause of blindness.

IPC Classes  ?

• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• A61P 27/02 - Ophthalmic agents
• C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Abstract

Disclosed herein are low dielectric constant (low-k) two-dimensional covalent organic framework materials that have a dielectric constant k less than 2.4, optionally less than 1.9, and are comprised of regularly porous, covalently linked, layer structures.

IPC Classes  ?

• C07F 5/04 - Esters of boric acids

Abstract

Provided are compositions and methods for treating and/or preventing seizure-induced death in subjects in need thereof. In some embodiments, the methods include methods for inducing an audiogenic seizure and/or seizure-induced death, treating and/or preventing death associated with seizures in subjects, preventing sudden unexpected death in epilepsy (SUDEP) in subjects, preventing and/or reducing the risk of death in subjects having SCN8A gain-of-function mutations, preventing or reducing the risk of death associated with tonic seizures in subjects, and preventing or reducing the risk of death associated with epileptic seizures in subjects. Also provided are animals that have been modified to carry gain-of-function SCN8A mutations and methods for using the same to identify compounds that have activity in treating and/or preventing seizures and/or seizure-induced death in subjects.

IPC Classes  ?

• A01K 67/027 - New breeds of vertebrates

Abstract

Disclosed are methods, including automated methods, for identifying a compound that impacts a characteristic of a lipid raft phase domain, a characteristic of a non-raft phase domain, and/or a characteristic of one or more membrane proteins. In some embodiments, the method comprises contacting a population of vesicles with a candidate compound, wherein a population of vesicles, wherein one or more vesicles in the population of optionally comprises one or more membrane proteins, with a candidate compound, wherein in a portion of the population of vesicles there is only a single detectable membrane phase and in a portion of the population of vesicles a membrane lipid raft phase domain and a membrane non-raft phase domain are phase separated; detecting a signal from the population of vesicles; and identifying the candidate compound as having an impact on a characteristic of a lipid raft phase domain, a characteristic of a non-raft phase domain, and/or a characteristic of one or more membrane proteins based on the signal. Systems and non-transitory computer readable medium comprising computer executable instructions embodied in a computer readable medium that when executed by a processor of a computer control the computer to perform steps of the method are also disclosed.

IPC Classes  ?

• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
• G01N 21/64 - Fluorescence; Phosphorescence
• G01N 33/92 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol

Abstract

Methods for treating coronavirus disease 2019 (COVID-19), the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections, are described. The methods can be used to reduce the severity of outcomes related to COVID-19, such as hospitalization and ventilation. For example, the methods can involve treatment of a subject with a therapeutic agent that degrades hyaluronan and/or an agent that neutralizes a hyaluronan receptor, e.g., CD44, such as an anti-CD44 antibody.

IPC Classes  ?

• A61K 31/728 - Hyaluronic acid
• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• A61P 31/14 - Antivirals for RNA viruses

Abstract

Methods and systems for producing graphene from spent lithium-ion batteries are disclosed. One method includes applying an acid leaching solution to an anode of a lithium-ion battery to produce expanded graphite, applying a hydrothermal process to the expanded graphite to produce purified graphite, and subjecting the purified graphite to a shear mixing process to produce dispersed graphene. In some examples, the shear mixing process is combined with a hydrogen passivation process, which collectively improves each of graphene quality, graphene conversion rate, and graphene production efficiency.

IPC Classes  ?

• C01B 32/19 - Preparation by exfoliation
• C01B 32/225 - Expansion; Exfoliation
• H01M 10/54 - Reclaiming serviceable parts of waste accumulators

Abstract

Provided herein is a previously unannotated IncRNA lying within exon six and 3′UTR of the LCK gene, labeled “HULLK” for Hormone-Upregulated IncRNA within LCK. HULLK is a novel IncRNA situated within the LCKgene that can serve as an oncogene in PCa. Accordingly, provided are methods and compositions for diagnosing and treating prostate cancer based on HULLK that regulates prostate cancer cell growth.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

An anxiety microdose intervention delivery system receives, from a plurality of biomarker sensors, a positional parameter associated with a user's position, a social parameter associated with a user's social interaction, and a set of physiological parameters associated with a user's physiological state. The system can determine, using a recommendation algorithm, that a user is in a possible state of anxiety. The system can generate, based at least in part on the determination that the user is in the possible state of anxiety, data for displaying microdose intervention content on the user device. The microdose intervention content can be configured to better manage the anxiety. The system can receive user interaction with the microdose intervention content and transmit a report of the user interaction with the intervention content.

IPC Classes  ?

• G08B 21/18 - Status alarms
• A61B 5/0205 - Simultaneously evaluating both cardiovascular conditions and different types of body conditions, e.g. heart and respiratory condition
• A61B 5/16 - Devices for psychotechnics; Testing reaction times

Abstract

A method for performing dynamic positron emission tomography (PET) is disclosed. The method includes collecting volumetric radioactive measurement data associated with an administered radioactive tracer present in a target site of a subject over multiple scanning intervals, capturing a magnetic resonance image of the target site, and performing a motion correction process to the volumetric radioactive measurement data to produce motion corrected PET data. The method further includes co-registering the magnetic resonance image and motion corrected data to generate a co-registered dynamic PET volume, and applying a model corrected input function (MCIF) to the co-registered dynamic PET volume to calibrate an uptake amount of the radioactive tracer in the target site.

IPC Classes  ?

• A61B 6/03 - Computerised tomographs
• A61B 6/00 - Apparatus for radiation diagnosis, e.g. combined with radiation therapy equipment
• A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
• G06T 7/30 - Determination of transform parameters for the alignment of images, i.e. image registration

Abstract

An insulin device configured to control insulin dispensing based on insulin sensitivity. The insulin device includes a processor configured to receive insulin dosing schedule information, psychological stress level data, and body mass index (BMI) data; a sensor configured to generate a blood glucose level measurement. The sensor is calibrated as a function of the psychological stress level data and the BMI data and the processor is configured to monitor and detect changes of the blood glucose level measurement that are determined to have occurred as a function of changes of the psychological stress level data, and identify a time when the BMI data counteracts a detected change in the blood glucose level measurement. The insulin device also includes an insulin dispensing valve controlled by the processor to change the insulin dosing schedule information in accordance with the counteracting BMI data.

IPC Classes  ?

• A61M 5/172 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters electrical or electronic
• G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
• G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
• G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
• A61M 5/142 - Pressure infusion, e.g. using pumps

Abstract

Some embodiments relate to therapeutic radioisotopic particles. In some embodiments, the therapeutic particles are radiolabeled with therapeutic radioisotopes. In some embodiments, the therapeutic particles can be in the treatment of cancer of the liver. In some embodiments, the therapeutic particles are radiolabeled with therapeutic radioisotopes. In some embodiments, the therapeutic radioisotope is directly coupled to a surface of a substrate of the particle.

IPC Classes  ?

• A61K 51/12 - Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes
• A61K 51/02 - Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier
• A61P 35/00 - Antineoplastic agents
• A61N 5/10 - X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
• G21G 4/08 - Radioactive sources other than neutron sources characterised by constructional features specially adapted for medical applications

Abstract

An exemplary method and system are disclosed that employ DENSE deep learning neural-network(s) trained with displacement-encoded imaging data (i.e., DENSE data) to estimate intramyocardial motion from cine MRI images and other cardiac medical imaging modalities, including standard cardiac computer tomography (CT) images, magnetic resonance imaging (MRI) images, echocardiogram images, heart ultrasound images, among other medical imaging modalities described herein. The DENSE deep learning neural-network(s) can be configured (trained) using (i) contour motion data from displacement-encoded imaging magnitude data as inputs to the neural network and (ii) displacement maps derived from displacement-encoded imaging phase images for comparison to the outputs of the neural network for neural network adjustments during the training.

IPC Classes  ?

• G06T 7/00 - Image analysis
• G06T 3/40 - Scaling of a whole image or part thereof
• G06T 7/246 - Analysis of motion using feature-based methods, e.g. the tracking of corners or segments
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Abstract

Provided are polypeptides that have at least about 95% but less than 100% sequence identity to SEQ ID NO: 2, optionally wherein the polypeptide has an amino acid sequence as set forth in SEQ ID NO: 4, with the proviso that the polypeptide does not have 100% sequence identity to SEQ ID NO: 2. Also provided are polypeptides that include an amino acid sequence that is a variant of SEQ ID NO: 2, wherein the variant sequence has at least one substitution at an amino acid position selected from the group consisting of D287, D291, D311, N313, D315, L307, and N284 of SEQ ID NO: 2; optionally wherein the polypeptide inhibits growth of a microbe and/or microbial biofilm and/or disrupts a microbial biofilm; nucleic acid molecules encoding the disclosed polypeptides; vectors and recombinant host cells that include the disclosed nucleic acid molecules; antimicrobial compositions that include an effective amount of the disclosed polypeptides, optionally that also include a carrier and/or one or more additional active agents; and methods for inhibiting the growth of microbes and/or microbial biofilms on surfaces and/or for disrupting microbial biofilms on surfaces and methods for inhibiting the growth of microbes on and/or in agricultural products and/or subjects.

IPC Classes  ?

• C07K 14/01 - DNA viruses
• A01N 37/46 - N-acyl derivatives
• A61L 2/16 - Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances

Abstract

An aspect of an embodiment or partial embodiment of the present invention (or combinations of various embodiments in whole or in part of the present invention) comprises, but not limited thereto, a method and system (and related computer program product) for continually assessing the risk of hypoglycemia for a patient and then determining what action to take based on that risk assessment. A further embodiment results in two outputs: (1) an attenuation factor to be applied to the insulin rate command sent to the pump (either via conventional therapy or via open or closed loop control) and/or (2) a red/yellow/green light hypoglycemia alarm providing to the patient an indication of the risk of hypoglycemia. The two outputs of the CPHS can be used in combination or individually.

IPC Classes  ?

• A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration, pH-value
• G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
• A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
• G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
• A61M 5/172 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters electrical or electronic
• G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation

Abstract

A method, system, and computer-readable medium are provided for a dual mode Closed-Loop Control (CLC) system integrating each of (i) an adaptive, personalized Model Predictive Control (MPC) control law that modulates the control strength of insulin infusion depending on recent past control actions, glucose measurements, and their derivative(s), (ii) an automatic Bolus Priming System (BPS) that commands additional insulin injections upon the detection of enabling metabolic conditions (e.g., an unannounced meal), and (iii) a hyperglycemia mitigation system (HMS) to avoid prevailing hyperglycemia.

IPC Classes  ?

• A61M 5/172 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters electrical or electronic
• G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation

Abstract

The present disclosure relates to compositions and methods related to tissue-specific promoters and their uses in plants, including tobacco and Cannabis. The provided trichome-specific promoters enable the expression of heterologous polynucleotides in trichome tissues.

IPC Classes  ?

• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells
• C07K 14/415 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
• C12P 5/00 - Preparation of hydrocarbons

Abstract

The invention relates to a methods and systems for determining an insulin dosing recommendation. The invention employs Linear Quadratic methodology to determine the insulin dosing recommendation based on a patient's present physiological state, which is estimated by an adaptive filter methodology employing a dynamic model, which utilizes real-time measurements of blood glucose concentration.

IPC Classes  ?

• A61M 5/172 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters electrical or electronic
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
• G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
• G16H 20/60 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to nutrition control, e.g. diets
• G16Z 99/00 - Subject matter not provided for in other main groups of this subclass
• G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
• G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection

Abstract

Compositions and methods for modifying the production levels of alkaloids in plants are provided. Alkaloid production can be genetically controlled by modulating the transcriptional activation of PMT genes mediated by members of the ERF family and/or Myc family of transcription factors. Novel nucleotide sequences encoding the Myc family of transcription factors are also provided.

IPC Classes  ?

• C07K 14/415 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells

Abstract

A multicompartment conductive collagen scaffold composite, comprising a scaffold comprising collagen and an electrically conductive material, optionally wherein the electrically conductive material comprises electrically conductive particles, and further comprising longitudinally aligned pores, and methods of making and using the same.

IPC Classes  ?

• A61L 27/56 - Porous or cellular materials
• A61L 27/38 - Animal cells
• A61L 27/26 - Mixtures of macromolecular materials
• A61N 1/05 - Electrodes for implantation or insertion into the body, e.g. heart electrode

Abstract

A technique for automated classification of biological subpopulations can include or use training a classifier by receiving an analyte biological specimen defining biophysical features characterized by corresponding electrical impedance parameters, within a test cell through which the biological specimen is flowing, measuring an electrical impedance of the biological specimen using a specified range of frequencies, extracting at least two electrical impedance parameters from the measured electrical impedance, and using the at least two electrical impedance parameters as an input to a trained classifier, training the classifier using training data from a plurality of other biological specimens and corresponding electrical impedance parameters of such training data.

IPC Classes  ?

• G01N 27/02 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance
• G01N 15/02 - Investigating particle size or size distribution

Abstract

Disclosed herein are systems, methods, and computer-readable media for sorting datasets within a Processing in Memory (PIM)-based system. A request to sort a dataset stored in a 3D-stacked memory can be received. The request can identify a specific dataset and sorting criteria, which includes a plurality of keys. The dataset can be partitioned into several subarrays across various memory banks within the 3D-stacked memory. Each piece of data within these subarrays can be separated into buckets based on the keys. Local histograms for each subarray and bank histograms based on the local histograms can be generated. A prefix-sum operation on the bank histograms can determine individual positions for the sorted dataset. Aggregation of the subarrays from all memory banks can form the sorted dataset, which can be subsequently returned.

IPC Classes  ?

• G06F 7/26 - Sorting, i.e. extracting data from one or more carriers, re-arranging the data in numerical or other ordered sequence, and re-recording the sorted data on the original carrier or on a different carrier or set of carriers the sorted data being recorded on the original record carrier within the same space in which the data had been recorded prior to their sorting, without using intermediate storage
• G06F 7/49 - Computations with a radix, other than binary, 8, 16 or decimal, e.g. ternary, negative or imaginary radices, mixed radix

Abstract

Provided are methods for treating tumors and/or cancers in subjects in need thereof. In some embodiments, the method include administering to the subject an inhibitor of a Rho-Associated Coiled-Coil Containing Protein Kinase 1 (ROCK1) 5 biological activity and/or a checkpoint inhibitor. In some embodiments, the cancer is a solid tumor. Also provided are compositions that have an effective amount of an inhibitor of a Rho-Associated Coiled-Coil Containing Protein Kinase 1 (ROCK1) biological activity and/or an effective amount of a checkpoint inhibitor; and an effective amount of a DR5 agonist, which can be a bispecific antibody; bispecific antibodies that has a first antigen binding site that is specific for the DRS polypeptide and a second antigen binding site that is specific for the ROCK1 polypeptide, the CTLA4 polypeptide, the PD-1 polypeptide, or the PD-L1 polypeptide; compositions for use in treating tumors and/or cancers, including bispecific antibodies.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 31/4439 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61P 35/00 - Antineoplastic agents

Abstract

An image calibration method includes capturing and correcting a flood field image for background signal and effects of known image-panel features (dead/bad pixels). The corrected image is processed to separate frequencies characteristic of relative pixel sensitivities from frequencies characteristic of radiation energy fluence. The incident energy fluence has a known maximum in-field energy fluence gradient. A model that describes the incident energy fluence on a detector is generated or received. The corrected image may be modeled at frequencies at or below the maximum in-field energy fluence gradient. A pixel sensitivity matrix (PSM) is generated by adjusting the corrected image with the model of the incident energy fluence on the detector. For example, the corrected image signal may be divided by the model or the model may be subtracted from the corrected image. The PSM may be used to correct additional raw images captured by the detector.

IPC Classes  ?

• A61N 5/10 - X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy

Abstract

A method and system are disclosed for efficient early detection of co-evolutionary sites among genomic sequences. Exemplary embodiments extract/approximate a data motif complex of a given data set wherein the extraction procedure can be performed using at least two steps. One step is construction of a vertex set of the data motif complex by identifying data sites with high informational variation. Another step is construction of higher dimensional simplices which systematically represent informational patterns within the data set. The method and system can be implemented as a computer-implemented software pipeline as described herein. An exemplary application can rapidly recognize key or critical mutational blocks in viral SARS-CoV-2 genomic data.

IPC Classes  ?

• G16B 40/30 - Unsupervised data analysis
• G16B 30/10 - Sequence alignment; Homology search

Abstract

An inlet duct for a gas turbine engine includes a particle separator, a scavenge duct, and a layer of material having a low coefficient of restitution. The particle separator including an outer wall spaced, an inner wall, and a splitter located radially between the outer wall and the inner wall. The scavenge duct is coupled with particle separator. The layer of material is located on at least one of the outer wall, the splitter, and the scavenge duct.

IPC Classes  ?

• F02C 7/052 - Air intakes for gas-turbine plants or jet-propulsion plants having provisions for obviating the penetration of damaging objects or particles with dust-separation devices

Abstract

Blurring and noise artifacts in magnetic resonance (MR) images caused by off-resonant image components may be corrected with convolutional neural networks, particularly feed forward networks with skip connections. Demodulating complex blurred images with off-resonant artifacts at a selected number of frequencies forms a respective real component frame of the MR data and a respective imaginary component frame for each image. A convolutional neural network is used to de-blur the images. The network has a plurality of residual blocks with multiple convolution calculations paired with respective skip connections. The method outputs, from the convolutional neural network, a de-blurred real image frame and a de-blurred imaginary image frame of the MR data for each complex blurred image.

IPC Classes  ?

• A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging

Abstract

Embodiments of the present disclosure include a walker equipped with one or more sensors, an onboard controller, powered wheels and associated motor controllers. The walker can sense its distance from the user and activate the powered wheels when commanded by the controller. The controller can execute programming including an automatic feedback control algorithm that regulates the distance between the walker frame and the user. In this manner, the walker automatically follows the user, keeping the user from having to expend energy to pull the walker along. The walker can then be utilized by the user solely for balance and support.

IPC Classes  ?

• A61H 3/04 - Wheeled walking aids for patients or disabled persons

Abstract

Disclosed herein is a Dynamic Random Access Memory-Based Content-Addressable Memory (DRAM-CAM) architecture and methods relating thereto. The DRAM-CAM architecture can include a memory array, with the data organized into blocks including rows and columns. Input data can be converted into a format with first and second groups of columns. Each first group can correspond to one or more rows of the input data, and each second group can include one or more null columns. A query can be received and loaded into an available column of the second group, and pattern matching can be performed on the data to identify occurrences of elements defined by the query. The pattern matching can be performed concurrently on the first groups of columns and the available columns bit by bit. Results can include a count or location of each identified element.

IPC Classes  ?

• G06F 16/22 - Indexing; Data structures therefor; Storage structures
• G06F 16/2455 - Query execution
• G06F 16/2453 - Query optimisation

Abstract

The present disclosure provides SPNS2 inhibitor compounds according to Formula (I) and their pharmaceutically acceptable salts, and/or tautomers as described in the disclosure, and the disclosure provides their pharmaceutical compositions and methods of use in therapy.

IPC Classes  ?

• C07D 271/06 - 1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
• C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond

Abstract

A damping mechanism for damping energy resulting from a lateral force on a structure may include a first portion, a second portion configured for longitudinal motion relative to the first portion, a primary energy absorption system configured for frictionally coupling the first portion and the second portion and converting motion of the second portion relative to the first portion into heat energy, and a secondary energy absorption system configured to absorb energy through non-linear deformation and provide a self-centering effect on the damping mechanism.

IPC Classes  ?

• E04H 9/02 - Buildings, groups of buildings or shelters adapted to withstand or provide protection against abnormal external influences, e.g. war-like action, earthquake or extreme climate withstanding earthquake or sinking of ground
• F16F 7/08 - Vibration-dampers; Shock-absorbers with friction surfaces rectilinearly movable along each other
• F16F 7/12 - Vibration-dampers; Shock-absorbers using plastic deformation of members

Abstract

Disclosed herein are silencing oligonucleotides useful to regulate, limit, or inhibit the expression of AVIL (advillin). Also disclosed herein are methods for treating disorders associated with AVIL dysregulation using same. In some embodiments, the method involves treating a cancer, such as glioblastomas, rhabdosarcomas, gliomas, lung cancer, bladder cancer, or renal cancer.

IPC Classes  ?

• A61K 31/506 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
• A61P 35/04 - Antineoplastic agents specific for metastasis
• A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

A structure, method, and computer program product for a diabetes control system provides, but is not limited thereto, the following: open-loop or closed-loop control of diabetes that adapts to individual physiologic characteristics and to the behavioral profile of each person. An exemplary aspect to this adaptation is biosystem (patient or subject) observation and modular control. Consequently, established is the fundamental architecture and the principal components for a modular system, which may include algorithmic observers of patients' behavior and metabolic state, as well as interacting control modules responsible for basal rate, insulin boluses, and hypoglycemia prevention.

IPC Classes  ?

• G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
• G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
• A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration, pH-value

Abstract

Disclosed herein are details of a hermetically or aseptically sealed bioreactor. The bioreactor comprises a bioreactor chamber, a membrane wall, a scaffold structure, a linear actuator, a linear transfer means, and a control system. Use of the bioreactor permits the inner scaffold structure to be moved and manipulated while still preserving a hermetic or aseptic seal inside the bioreactor chamber during operation.

IPC Classes  ?

• C12M 1/12 - Apparatus for enzymology or microbiology with sterilisation, filtration, or dialysis means
• C12M 1/00 - Apparatus for enzymology or microbiology
• C12M 3/00 - Tissue, human, animal or plant cell, or virus culture apparatus

Abstract

Provided are methods for treating macular degeneration, optionally macular degeneration, in subject in need thereof. In some embodiments, the methods include administering to a subject in need thereof a therapeutically effective amount of fluoxetine in an amount and via a route sufficient to treat or prevent development of macular degeneration in the subjects. Also provided are methods for inhibiting activation of an NLRP3-ASC inflammasome in the subjects, inhibiting ASC speck formation in the subjects, inhibiting Alu RNA-induced RPE degeneration in the subjects, and treatment and/or prevention of the development of diseases, disorders, and/ or conditions.

IPC Classes  ?

• A61K 31/138 - Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
• A61P 27/12 - Ophthalmic agents for cataracts

Abstract

The presently disclosed subject matter provides devices, systems, and methods for model inter-organ communication. In some embodiments, a multi-organ-on-a-chip (MOC) system can include one or more micro-culture well configured to receive a live tissue sample therein and an impeller-based pump in fluid communication with the one or more micro-culture well. In this arrangement, the impeller-based pump can be configured to generate fluid flow through the one or more micro-culture well.

IPC Classes  ?

• C12M 3/00 - Tissue, human, animal or plant cell, or virus culture apparatus
• C12M 3/06 - Tissue, human, animal or plant cell, or virus culture apparatus with filtration, ultrafiltration, inverse osmosis or dialysis means
• C12M 1/42 - Apparatus for the treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic wave

Abstract

A method, system, and computer-readable medium are provided for modeling a time-varying representation of the glucose homeostasis of a patient with Type 1 diabetes (T1D) according to a computational model therefor. The model implements a reconstruction of data supporting a glucose time series for the patient, and based on the reconstruction, further implements model personalization and a variability control (VC) signal accounting for insulin sensitivity so as to enable the patient to learn an effect of adjustment to one or more portions of the data. Such knowledge is acquired upon a replay of the reconstruction implementing the adjustment.

IPC Classes  ?

• G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
• G16H 20/60 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to nutrition control, e.g. diets
• G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders

Abstract

An integrated circuit memory device can include a plurality of banks of memory, each of the banks of memory including a first pair of sub-arrays comprising first and second sub-arrays, the first pair of sub-arrays configured to store data in memory cells of the first pair of sub-arrays, a first row buffer memory circuit located in the integrated circuit memory device adjacent to the first pair of sub-arrays and configured to store first row data received from the first pair of sub-arrays and configured to transfer the row data into and/or out of the first row buffer memory circuit, and a first sub-array level processor circuit in the integrated circuit memory device adjacent to the first pair of sub-arrays and operatively coupled to the first row data, wherein the first sub-array level processor circuit is configured to perform column oriented processing a sparse matrix kernel stored, at least in-part, in the first pair of sub-arrays, with input vector values stored, at least in part, in the first pair of sub-arrays to provide output vector values representing products of values stored in columns of the sparse matrix kernel with the input vector values.

IPC Classes  ?

• G11C 7/10 - Input/output [I/O] data interface arrangements, e.g. I/O data control circuits, I/O data buffers
• G06F 17/16 - Matrix or vector computation

Abstract

Systems and methods are disclosed for generating cluster quantum states usable for quantum computing. An example system can generate a plurality of qumodes. The plurality of qumodes can include at least two successive qumodes in frequency domain, wherein a frequency spacing between two successive qumodes is equal to a free-spectral range of an optical frequency comb. The plurality of qumodes can include a plurality of bipartite entangled states. A cluster quantum state can be generated by modulating a phase of a portion of the optical fields associated with the plurality of qumodes received from the optical frequency comb, at one or more modulation frequencies. In some embodiments, each of the one or more modulation frequencies can be equal to an integral multiple of the free-spectral-range. In certain embodiments, a property of a cluster graph (such as a dimension of the cluster graph) associated with the cluster quantum state can be controlled by adjusting one or more modulation frequencies.

IPC Classes  ?

• G02F 1/39 - Non-linear optics for parametric generation or amplification of light, infrared, or ultraviolet waves
• G02F 1/35 - Non-linear optics
• G06N 10/40 - Physical realisations or architectures of quantum processors or components for manipulating qubits, e.g. qubit coupling or qubit control

Abstract

MR image data can be improved by using a complex de-noising convolutional neural network such as a non-blind C-DnCNN, a network for MRI denoising that leverages complex-valued data with phase information and noise level information to improve denoising performance in various settings. The proposed method achieved superior performance on both simulated and in vivo testing data compared to other algorithms. The utilization of complex-valued operations allows the network to better exploit the complex-valued MRI data and preserve the phase information. The MR image data is subject to complex de-noising operations directly and simultaneously on both real and imaginary parts of the image data. Complex and real values are also utilized for block normalization and rectified linear units applied to the noisy image data. A residual image is predicted by the C-DnCNN and a clean MR image is available for extraction.

IPC Classes  ?

• G06T 5/00 - Image enhancement or restoration
• G06T 5/50 - Image enhancement or restoration by the use of more than one image, e.g. averaging, subtraction
• G06T 11/00 - 2D [Two Dimensional] image generation

Abstract

An apparatus related method for measuring a property of a target material. The system may include a pump device that generates a pump beam. A modulation device may receive the pump beam and generate a modulated pump beam by modulating an intensity amplitude of the pump beam, which may be directed to the target material. A probe device may generate a probe beam, which is directed to the target material. A part of the probe beam may be reflected off of the target material, and has similar frequency characteristic as the modulated pump beam. A detection device may detect the reflected probe beam and produce a signal. An analyzing device may receive the signal and calculate the target material property by comparing the modulated frequency characteristics of the signal to those of the pump beam. At least one of the pump and the probe beams may be infrared light.

IPC Classes  ?

• G01N 21/55 - Specular reflectivity
• G01N 21/17 - Systems in which incident light is modified in accordance with the properties of the material investigated
• G01B 11/06 - Measuring arrangements characterised by the use of optical techniques for measuring length, width, or thickness for measuring thickness

Abstract

The present disclosure provides SPNS2 inhibitor compounds according to Formula (IA) and Formula (I), and their pharmaceutically acceptable salts, and/or tautomers as described in the disclosure, and the disclosure provides their pharmaceutical compositions and methods of use in therapy.

IPC Classes  ?

• C07C 225/10 - Compounds containing amino groups and doubly-bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly-bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated and containing rings with doubly-bound oxygen atoms bound to carbon atoms not being part of rings
• C07D 211/56 - Nitrogen atoms
• C07D 277/82 - Nitrogen atoms
• C07D 207/14 - Nitrogen atoms not forming part of a nitro radical
• C07D 207/12 - Oxygen or sulfur atoms
• C07D 263/58 - Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
• C07D 241/04 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
• C07D 211/34 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
• C07D 207/16 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Abstract

The present invention provides novel bispecific antibodies that bind to human CD30 and uses thereof. Methods of treating cancer using the bispecific antibodies described herein are also provided.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61P 35/00 - Antineoplastic agents
• A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum

Abstract

An aspect of an embodiment or partial embodiment of the present invention (or combinations of various embodiments in whole or in part of the present invention) comprises, but not limited thereto, a method and system (and related computer program product) for continually assessing the risk of hypoglycemia for a patient and then determining what action to take based on that risk assessment. A further embodiment results in two outputs: (1) an attenuation factor to be applied to the insulin rate command sent to the pump (either via conventional therapy or via open or closed loop control) and/or (2) a red/yellow/green light hypoglycemia alarm providing to the patient an indication of the risk of hypoglycemia. The two outputs of the CPHS can be used in combination or individually.

IPC Classes  ?

• A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration, pH-value
• G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
• A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
• G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
• A61M 5/172 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters electrical or electronic
• G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation

Abstract

A method for quantifying bacterial spore germination can include creating an ex vivo assay including bacteria spores and a homogenized stool sample. The ex vivo assay can be loaded into a microfluidic chip. Vegetative bacteria and the bacteria spores can be detected by sampling the mixture in the microfluidic chip using impedance cytometry to assess disruption of host microbiota.

IPC Classes  ?

• C12Q 1/04 - Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
• G01N 15/10 - Investigating individual particles

Abstract

Systems and methods for 3D bioprinting of hydrogel voxels enable microfluidics-assisted digital assembly of spherical particles (DASP). The systems include a 3D motion system, a microfluidic printhead coupled to the 3D motion system, an extrusion device fluidly coupled to the microfluidic printhead, and a sacrificial support matrix. The sacrificial support matrix is designed to support the hydrogel voxels during printing and cross-link the hydrogel voxels. The system includes bio-inks comprising hydrogel compositions having independently controllable viscoelasticity and mesh size. The bio-inks are extruded by the extrusion device and microfluidic printhead to produce the hydrogel voxels. Exploiting the microfluidic printhead enables printing individual spherical hydrogel voxels with diameters from 150 micrometers (μm) to 1200 μm. Positioning and interconnection of the hydrogel voxels can be precisely controlled. The systems and methods produce free-standing 3D structures and can be used for producing functional tissue mimics.

IPC Classes  ?

• B29C 64/106 - Processes of additive manufacturing using only liquids or viscous materials, e.g. depositing a continuous bead of viscous material
• B29C 64/40 - Structures for supporting 3D objects during manufacture and intended to be sacrificed after completion thereof
• B29C 64/209 - Heads; Nozzles
• B29C 64/393 - Data acquisition or data processing for additive manufacturing for controlling or regulating additive manufacturing processes
• B29C 64/227 - Driving means
• B81C 1/00 - Manufacture or treatment of devices or systems in or on a substrate

Abstract

Methods for sensitizing tumors and/or cancers in subjects to therapeutic agents are provided. In some embodiments, the methods include administering to the subject one or more compositions that include an effective amount of an inhibitor of TRIM37 activity. Also provided are methods for sensitizing tumors and/or cancers in subjects to therapeutic agents by administering to the subjects one or more compositions that include an effective amount of an inhibitor of TRIM37 activity and purified and isolated antibodies and fragments thereof that have at least one paratope and further have a linker sequence through which the antibody can be conjugated to a carrier in which the linker sequence includes the amino acid sequence ((X)3Cys(X)3, wherein each X is independently any amino acid.

IPC Classes  ?

• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61P 35/00 - Antineoplastic agents

Abstract

Compositions and methods are provided that are useful for diagnosing, treating, and monitoring alcohol dependence and disorders, susceptibility to alcohol dependence disorders, as well as drug related dependence and disorders. The methods include treating patients with an antagonist of the serotonin receptor 5-HT3 for such disorders, wherein the patient's serotonin transporter gene SLC6A4 is known to have particular genotypes.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
• A61K 31/4178 - 1,3-Diazoles not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
• A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• C12Q 1/6888 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
• G16B 20/00 - ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations

Abstract

A method for analyzing respiratory kinematics includes collecting a plurality of kinematic signal data streams from each of a respective plurality of inertial sensor devices applied to a subject, wherein the kinematic signal data streams are synchronized with each other, transforming the plurality of kinematic signal data streams into a respective plurality of analytic signals, determining landmark points associated with each of the plurality of analytic signals to identify individual breathing intervals associated with each of the plurality of inertial sensor devices, and analyzing two or more of the individual breathing intervals to establish a magnitude-synchronicity relationship that is utilized to determine a probability of a presence of a respiratory condition existing in the subject.

IPC Classes  ?

• A61B 5/113 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb occurring during breathing
• A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons

Abstract

A structure, method, and computer program product for a diabetes control system provides, but is not limited thereto, the following: open-loop or closed-loop control of diabetes that adapts to individual physiologic characteristics and to the behavioral profile of each person. An exemplary aspect to this adaptation is biosystem (patient or subject) observation and modular control. Consequently, established is the fundamental architecture and the principal components for a modular system, which may include algorithmic observers of patients' behavior and metabolic state, as well as interacting control modules responsible for basal rate, insulin boluses, and hypoglycemia prevention.

IPC Classes  ?

• G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
• A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration, pH-value
• A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
• G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Abstract

Compositions and methods are provided that are useful for diagnosing, treating, and monitoring alcohol dependence and disorders, susceptibility to alcohol dependence disorders, as well as drug related dependence and disorders. The methods include treating patients with an antagonist of the serotonin receptor 5-HT3 for such disorders, wherein the patient's serotonin transporter gene SLC6A4 is known to have particular genotypes.

IPC Classes  ?

• A61K 31/4178 - 1,3-Diazoles not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
• G16B 20/00 - ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• C12Q 1/6888 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
• A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin

Abstract

Inflammatory cell recruitment to local sites of tissue injury and/or infection is controlled by many signaling processes influencing cell-to-cell interactions between vascular endothelial cells (EC) in post-capillary venules and circulating leukocytes. Here we report that the ATP-release channel Pannexin1 (Panx1) opens downstream of EC activation by tumor necrosis factor α (TNFα). This process involves activation of Type 1 TNF receptors, recruitment of Src Family Kinases (SFK), and SFK-dependent phosphorylation of Panx1. We report a previously unidentified role for Panx1 channels in promoting leukocyte adhesion and emigration through the venous wall during acute systemic inflammation. The present application further discloses that Panx IL2 peptide consisting of amino acid sequence KYPIVEQYLKYGRKKQRR (SEQ ID NO:3) or 10Panx1 peptide consisting of amino acid sequence WRQAAFVDSY (SEQ ID NO:8) are inhibitors of leukocyte adhesion.

IPC Classes  ?

• A61K 38/20 - Interleukins
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
• A61P 7/00 - Drugs for disorders of the blood or the extracellular fluid
• A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• C07K 14/435 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans

Abstract

Provided are methods and kits for detecting an extrachromosomal circular DNA (eccDNA) in a biological sample. In some embodiments, the method comprises treating the biological sample to produce a tagged linearized fragment of genomic DNA; and determining whether the tagged linearized fragment is derived from an eccDNA to thereby detect the eccDNA. In some embodiments, the treating of the biological sample to produce a tagged linearized fragment of genomic DNA comprises treating the biological sample with an insertional enzyme complex to produce a tagged linearized fragment of genomic DNA.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA

Abstract

The present disclosure provides for a rhodium-catalyzed oxidative arene alkenylation from arenes and styrenes to prepare stilbene and stilbene derivatives. For example, the present disclosure provides for method of making arenes or substituted arenes, in particular stilbene and stilbene derivatives, from a reaction of an optionally substituted arene and/or optionally substituted styrene. The reaction includes a Rh catalyst or Rh pre-catalyst material and an oxidant, where the Rh catalyst or Rh catalyst formed Rh pre-catalyst material selectively functionalizes CH bond on the arene compound (e.g., benzene or substituted benzene).

IPC Classes  ?

• C07C 2/84 - Preparation of hydrocarbons from hydrocarbons containing a smaller number of carbon atoms by condensation of hydrocarbons with partial elimination of hydrogen oxidative coupling catalytic
• C07C 41/30 - Preparation of ethers by reactions not forming ether-oxygen bonds by increasing the number of carbon atoms, e.g. by oligomerisation
• C07C 17/266 - Preparation of halogenated hydrocarbons by reactions involving an increase in the number of carbon atoms in the skeleton by condensation reactions of hydrocarbons and halogenated hydrocarbons
• C07C 201/12 - Preparation of nitro compounds by reactions not involving the formation of nitro groups
• C07C 253/30 - Preparation of carboxylic acid nitriles by reactions not involving the formation of cyano groups
• C07D 307/36 - Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
• B01J 31/22 - Organic complexes

Abstract

Methods for treating coronavirus disease 2019 (COVID-19), the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections, is described. The methods can be used to reduce the severity of outcomes related to COVID-19, such as hospitalization and ventilation. For example, treatment of a subject with a therapeutic agent that neutralizes interleukin 13 (IL-13) can result in reduced risk for mechanical ventilation in the subject. Also described are methods of predicting risk of mechanical ventilation in subjects with COVID-19.

IPC Classes  ?

• C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
• A61K 31/519 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings

Abstract

Methods for inhibiting or treating viral infection in a subject infected with a vims of the arenaviridae family with a therapeutic agent combination: (a) arbidol and aripiprazole; (b) arbidol and amodiaquine; (c) arbidol and sertraline; (d) arbidol, iprazole, and amodiaquine; (e) arbidol, aripiprazole, and sertraline; or (f) aripiprazole and amodiaquine; or pharmaceutically acceptable salts thereof.

IPC Classes  ?

• A61K 31/4045 - Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
• A61K 31/47 - Quinolines; Isoquinolines
• A61K 31/135 - Amines, e.g. amantadine having aromatic rings, e.g. methadone
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 31/14 - Antivirals for RNA viruses

Abstract

0.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
• A01K 29/00 - Other apparatus for animal husbandry
• A61B 5/0205 - Simultaneously evaluating both cardiovascular conditions and different types of body conditions, e.g. heart and respiratory condition
• A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration, pH-value
• A61M 5/172 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters electrical or electronic
• G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• A61B 5/11 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
• A61M 5/142 - Pressure infusion, e.g. using pumps

Abstract

Embodiments of the present disclosure provide for Rh(I) catalysts, methods of making alkenyl substituted arenes (e.g., allyl arene, vinyl arene, and the like), methods of making alkyl substituted arenes, and the like.

IPC Classes  ?

• C07C 2/66 - Catalytic processes
• B01J 31/18 - Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes containing nitrogen, phosphorus, arsenic or antimony
• B01J 31/22 - Organic complexes
• B01J 31/00 - Catalysts comprising hydrides, coordination complexes or organic compounds
• C07C 5/03 - Preparation of hydrocarbons from hydrocarbons containing the same number of carbon atoms by hydrogenation of non-aromatic carbon-to-carbon double bonds

Abstract

The presently disclosed subject matter relates to a method for characterizing a protein. The method can comprise disposing a protein in a digestion buffer; disposing a hydrolyzing agent inhibitor in the digestion buffer; passing the digestion buffer comprising said protein and said hydrolyzing agent inhibitor through a reaction chamber comprising at least one hydrolyzing agent, wherein said protein contacts said hydrolyzing agent in the presence of said inhibitor and is present in the chamber for a period of time (t) sufficient to produce protein fragments and provide digestion of said protein in the chamber, wherein the passing of the digestion buffer comprising the protein and the hydrolyzing agent inhibitor through the chamber is done at an adjustable flow rate; and performing multi-segment liquid chromatography tandem mass spectrometry (LC MS/MS) to characterize the protein.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells

Abstract

Disclosed aspects include characterizing of the metabolite secretome of apoptotic cells, deciphering metabolite-based communication between dying cells and neighboring live cells, and harnessing components of the secretome for beneficial effects in vivo. In representative embodiments, a composition comprising, consisting essentially of, or consisting of an effective amount of a plurality of metabolite compounds derived from an apoptotic cell is disclosed, as are methods of treating an inflammatory condition in a subject and modulating gene expression in a subject using the composition.

IPC Classes  ?

• A61K 31/132 - Amines, e.g. amantadine having two or more amino groups, e.g. spermidine, putrescine
• A61K 31/661 - Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

Methods for treating and/or inhibiting progression of diseases, conditions, and/or disorders. In some embodiments, the methods include administering to as subject in need thereof a composition that includes a nucleoside reverse transcriptase inhibitor (NRTIs), an NRTI metabolite, an NRTI analog, a pharmaceutically acceptable salt and/or metabolite thereof, a prodrug of an NRTI, or any combination thereof. Also provided are methods for inhibiting development of macular degeneration in subjects; methods for inhibiting development and/or progression of viral infection and/or a disease, condition, disorder, and/or symptom associated therewith in a subject in need thereof; methods for inhibiting development and/or progression of acute respiratory distress syndrome in subjects; methods for inhibiting development and/or progression of cytokine storm syndrome in subjects; methods for inhibiting development and/or progression of fibrosis in subjects, and compositions for use in the presently disclosed methods.

IPC Classes  ?

• A61K 31/7072 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
• A61K 31/513 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 27/02 - Ophthalmic agents
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

The present disclosure relates to novel and improved methods of analyzing proteins, peptides and polypeptides by mass spectrometry using ion-ion reactions. More specifically the disclosure relates to improved methods for implementing the m/z selective arresting of ion-ion reactions within the ion-ion reaction cell of a mass spectrometer system during a period where ion-ion reactions are performed.

IPC Classes  ?

• H01J 49/00 - Particle spectrometers or separator tubes
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
• H01J 49/04 - Arrangements for introducing or extracting samples to be analysed, e.g. vacuum locks; Arrangements for external adjustment of electron- or ion-optical components
• H01J 49/42 - Stability-of-path spectrometers, e.g. monopole, quadrupole, multipole, farvitrons

Abstract

Methods of detecting SARS-CoV-2 antibodies with improved specificity are described. The methods can include contacting a sample potentially containing SARS-CoV-2 antibodies with a reagent to remove non-anti-SARS-CoV-2 antibodies, such as a reagent comprising an epitope from a nucleocapsid protein or spike protein of a common coronavirus. The methods can include contacting the sample with a mutant SARS-CoV-2 nucleocapsid protein or spike protein comprising a reduced number of common coronavirus epitopes. The methods can involve comparing results from an immunoassay performed with a SARS-CoV-2 protein to results obtained from immunoassays performed with analogous protein from one or more common coronaviruses.

IPC Classes  ?

• G01N 33/543 - Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Abstract

Disclosed are compositions and methods that can be used for the prevention, mitigation, and/or prophylactic treatment of a viral infection, such but not limited to a coronavirus infection, such as but not limited to a COVID-19 infection. In some embodiments, a chemically modified tetracycline (CMT) derivative for the prevention, mitigation and/or prophylactic treatment of a viral infection is provided. In some embodiments, the CMT derivative lacks anti-microbial activity; comprises a phenol ring; and/or comprises a chemical structure sufficient to chelate and/or bind a divalent cation. In some embodiments, the divalent cation comprises Zn2+. In some embodiments, the viral infection is a coronavirus infection. In some embodiments, the viral infection is a COVID-19 infection.

IPC Classes  ?

• A61K 31/65 - Tetracyclines
• A61P 31/14 - Antivirals for RNA viruses
• A61K 33/30 - Zinc; Compounds thereof

Abstract

Provided are a system and method for predicting risk of diagnosis for Autism Spectrum Disorder (ASD) using neonatal analytics. Such analytics assess heart rate pattern data for a given period of admission in a Neonatal Intensive Care Unit to determine correlation with heart rate characteristics indicative of ASD. Relative to a finding of one or more correlations, such analytics offer the opportunity for earliest screening and intervention for ASD, as appropriate.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
• A61B 5/024 - Measuring pulse rate or heart rate
• G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment

Abstract

The present disclosure provides soluble mutant PD-L1 peptides, polynucleotides and vectors encoding the peptides, and methods of using the peptides to elicit differentiation of regulatory T cells.

IPC Classes  ?

• C12N 5/0783 - T cells; NK cells; Progenitors of T or NK cells
• C07K 14/705 - Receptors; Cell surface antigens; Cell surface determinants

Abstract

An aspect of an embodiment or partial embodiment of the present invention (or combinations of various embodiments in whole or in part of the present invention) comprises, but not limited thereto, a method and system (and related computer program product) for continually assessing the risk of hypoglycemia for a patient and then determining what action to take based on that risk assessment. A further embodiment results in two outputs: (1) an attenuation factor to be applied to the insulin rate command sent to the pump (either via conventional therapy or via open or closed loop control) and/or (2) a red/yellow/green light hypoglycemia alarm providing to the patient an indication of the risk of hypoglycemia. The two outputs of the CPHS can be used in combination or individually.

IPC Classes  ?

• A61M 31/00 - Devices for introducing or retaining media, e.g. remedies, in cavities of the body
• A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration, pH-value
• G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
• A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
• G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
• A61M 5/172 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters electrical or electronic
• G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
• G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation

Abstract

This disclosure is directed to a high-speed avalanche photodiode device configured to detect single photons. The avalanche photodiode device may include a passive quenching circuitry. The passive quenching circuitry may include a quenching resistor having a resistivity spontaneously adaptive to a bias voltage applied across the quenching resistor. Such adaptive resistivity enables a fast response time for the avalanche photodiode device when used to detect single photos in Geiger mode.

IPC Classes  ?

• H01L 31/02 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof - Details

Abstract

The present disclosure provides azetidine compounds of Formula I and their pharmaceutically acceptable salts, their compositions, and methods for their use in determining azetidine compound binding to proteins. The azetidine compounds are useful as probes, for monitoring diacylglycerol kinase activity, and for identifying druggable targets.

IPC Classes  ?

• C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 205/04 - Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
• C07D 205/12 - Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

The present invention relates methods of treating cytokine storm syndrome comprising administering to a patient in need thereof a therapeutically effective amount of an adenosine A2A receptor agonist.

IPC Classes  ?

• A61K 31/7076 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
• A61K 31/519 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/404 - Indoles, e.g. pindolol
• A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
• A61P 31/14 - Antivirals for RNA viruses
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

An image calibration method includes capturing and correcting a flood field image for background signal and effects of known image-panel features (dead/bad pixels). The corrected image is processed to separate frequencies characteristic of relative pixel sensitivities from frequencies characteristic of radiation energy fluence. The incident energy fluence has a known maximum in-field energy fluence gradient. A model that describes the incident energy fluence on a detector is generated or received. The corrected image may be modeled at frequencies at or below the maximum in-field energy fluence gradient. A pixel sensitivity matrix (PSM) is generated by adjusting the corrected image with the model of the incident energy fluence on the detector. For example, the corrected image signal may be divided by the model or the model may be subtracted from the corrected image. The PSM may be used to correct additional raw images captured by the detector.

IPC Classes  ?

• A61N 5/10 - X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy

Abstract

An electrochemical device for identifying electroactive analytes. The device includes a substrate; a sample region; a counter electrode; a reference electrode; a working electrode disposed in communication with the substrate, and the working electrode may be an electron conducting fiber. Further, the counter electrode, reference electrode, and working electrode are partially disposed in the sample region configured to be exposed to the electroactive analyte. Further yet, a counter electrode channel, reference electrode channel, and working electrode channel are disposed in the substrate configured to: accommodate each of the counter electrode, reference electrode, and working electrode, respectively, for placement in the respective channels.

IPC Classes  ?

• G01N 27/327 - Biochemical electrodes
• H01L 51/00 - Solid state devices using organic materials as the active part, or using a combination of organic materials with other materials as the active part; Processes or apparatus specially adapted for the manufacture or treatment of such devices, or of parts thereof
• B82Y 10/00 - Nanotechnology for information processing, storage or transmission, e.g. quantum computing or single electron logic
• B82Y 40/00 - Manufacture or treatment of nanostructures
• B82Y 15/00 - Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors

Abstract

An ion conducting polymer comprising a modified poly(phenylene oxide) is described. In an exemplary modified polymer, a portion of the monomeric units are attached to a sulfonate-substituted arylamino moiety, such as a monovalent derivative of phenoxy aniline trisulfonate (BOATS), to form a monomeric unit with a charged side chain. Ion conducting polymers can also be prepared with polyether-containing side chains. The ion conducting polymer can be used to prepare ion exchange membranes which can be used in a variety of applications, such as in non-aqueous redox flow batteries and related energy storage systems.

IPC Classes  ?

• C08L 71/12 - Polyphenylene oxides
• B01J 41/13 - Macromolecular compounds obtained otherwise than by reactions only involving unsaturated carbon-to-carbon bonds
• C08G 65/48 - Polymers modified by chemical after-treatment
• H01M 50/423 - Polyamide resins
• H01M 8/103 - Polymeric electrolyte materials characterised by the chemical structure of the main chain of the ion-conducting polymer having nitrogen, e.g. sulfonated polybenzimidazoles [S-PBI], polybenzimidazoles with phosphoric acid, sulfonated polyamides [S-PA] or sulfonated polyphosphazenes [S-PPh]
• H01M 8/18 - Regenerative fuel cells, e.g. redox flow batteries or secondary fuel cells
• H01M 8/04082 - Arrangements for control of reactant parameters, e.g. pressure or concentration
• H01M 8/04186 - Arrangements for control of reactant parameters, e.g. pressure or concentration of liquid-charged or electrolyte-charged reactants
• C25B 13/08 - Diaphragms; Spacing elements characterised by the material based on organic materials

Abstract

Embodiments relate to systems and methods for informing, determining, or controlling insulin dosage. The method involves generating plural disturbance profiles, each disturbance profile being a data representation based on historical patient data pertaining to a deviation from a threshold blood glucose level. The method involves receiving current patient data. The method involves applying a predictive model so that current patient data is compared to a disturbance profile and a probability analysis is used to assess the likelihood of a disturbance profile being an anticipated disturbance profile, the anticipated disturbance profile being a disturbance profile that is determined to match with the current patient data based on the probability analysis. The method involves determining an insulin dose amount based on the anticipated disturbance profile. The method involves outputting a signal representative of the insulin dose amount to a device configured for monitoring, influencing, and/or administering insulin levels in the patient.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
• A61B 5/11 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
• A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration, pH-value
• G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection

Abstract

Methods and compositions for treating cancer, including brain cancers such as diffuse intrinsic pontine glioma (DIPG) and glioblastoma (GBM), breast cancers, melanomas, cervical cancers, bladder cancers, lung cancers, neuroblastomas, and rhabdomyosarcomas (RMS), are described. Also described are methods of preparing cells comprising chimeric antigen receptors (CARs), such as CAR T cells, that target integrin alphav beta3 (αvβ3).

IPC Classes  ?

• A61K 35/17 - Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
• A61P 35/00 - Antineoplastic agents
• C07K 14/725 - T-cell receptors
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C12N 15/86 - Viral vectors

Abstract

The present disclosure relates to targeting of miRNA to activate expression of genes on the inactivated X chromosome. This gene therapy is useful for treating X-linked disorders, including Rett syndrome.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 15/86 - Viral vectors
• A61P 25/00 - Drugs for disorders of the nervous system

Abstract

Apparatus includes a plurality of memory cells (e.g., a dynamic random access memory (DRAM)) addressable as rows and columns and a plurality of matching circuits configured to be coupled to respective bit lines associated with the columns A control circuit is configured to store respective reference sequences (e.g., binary-encoded k-mer patterns) in respective ones of the columns, to sequentially provide rows of bits stored in the memory cells and bits of a query to the matching circuits, and to identify one of the reference sequences as corresponding to the query responsive to comparisons by the matching circuits.

IPC Classes  ?

• G11C 15/00 - Digital stores in which information comprising one or more characteristic parts is written into the store and in which information is read-out by searching for one or more of these characteristic parts, i.e. associative or content-addressed stores
• G11C 7/10 - Input/output [I/O] data interface arrangements, e.g. I/O data control circuits, I/O data buffers
• H03K 19/20 - Logic circuits, i.e. having at least two inputs acting on one output; Inverting circuits characterised by logic function, e.g. AND, OR, NOR, NOT circuits
• G11C 7/12 - Bit line control circuits, e.g. drivers, boosters, pull-up circuits, pull-down circuits, precharging circuits, equalising circuits, for bit lines

Abstract

System and associated methods of use for rapid assessment of visual field integrity. In one embodiment, the device comprises a frame that rests near a patient’s eyes with pinpoint lights or mechanical stimuli that act as visual stimuli mounted at locations within the frame and in the patient’s peripheral visual field. A vantage point in front of the frame allows an operator to view the patient’s eyes during assessment, enabling the operator to maximize the accuracy during both in person and telemedicine assessments. The lights or mechanical stimuli are positioned such that they are visible to patients with a wide range of interpupillary distances, enabling the use of a single-size device for all patients.

IPC Classes  ?

• A61B 3/024 - Subjective types, i.e. testing apparatus requiring the active assistance of the patient for determining the visual field, e.g. perimeter types
• A61B 3/00 - Apparatus for testing the eyes; Instruments for examining the eyes

Abstract

In some embodiments herein, methods, compositions, and uses for modulating lymphatic vessels of the central nervous system are described. In some embodiments, methods, compositions, or uses for treating, preventing, or ameliorating symptoms of a neurological disease comprise increasing flow via meningeal lymphatic vessels are described.

IPC Classes  ?

• A61K 38/18 - Growth factors; Growth regulators
• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The capillary transfer technology presented here represents a powerful approach to transfer soft films from surface of liquid onto a solid substrate in a fast and defect-free manner. The fundamental theoretical model and transfer criteria validated with comprehensive experiments and finite element analyses, for the first time provides a quantitative guide and optimization for the choice of material systems, operating conditions and environments for scalable on-demand transfers with high yield. The intrinsically moderate capillary transfer force and externally selectable transfer direction offer robust capabilities for achieving deterministic assembly and surface properties of structures with complex layouts and patterns for potentially broad applications in the fabrication of flexible/stretchable electronics, surface wetting structures and optical devices. Integration of this technology with other advanced manufacturing technologies associated with material self-assembly, growth and layout alignment represents promising future topics and would help create emerging new manufacturing technologies that leverage unique fluidity of liquid environments.

IPC Classes  ?

• H05K 3/20 - Apparatus or processes for manufacturing printed circuits in which conductive material is applied to the insulating support in such a manner as to form the desired conductive pattern by affixing prefabricated conductor pattern
• B44C 1/175 - Transfer using solvent

Abstract

Sphingosine kinases are enzymes that catalyze the biosynthesis of sphingosine-1-phosphate. The invention provides prodrugs of compounds that are effective for inhibition of sphingosine kinase type 1, sphingosine kinase type 2, or both, according to formula (I) as described herein. Formula I compounds are useful in the treatment of a range of diseases wherein increasing the level of sphingosine-1-phosphate in blood is medically indicated. The invention also provides pharmaceutical compositions of Formula I compounds. Sphingosine kinases are enzymes that catalyze the biosynthesis of sphingosine-1-phosphate. The invention provides prodrugs of compounds that are effective for inhibition of sphingosine kinase type 1, sphingosine kinase type 2, or both, according to formula (I) as described herein. Formula I compounds are useful in the treatment of a range of diseases wherein increasing the level of sphingosine-1-phosphate in blood is medically indicated. The invention also provides pharmaceutical compositions of Formula I compounds.

IPC Classes  ?

• C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
• C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond

Abstract

Methods and compositions for treating cancer in a subject in need thereof. The method includes administering to the subject an effective amount of a composition comprising Tumor-Targeting Effectors (TITE) derived from a culture comprising a bispecific antibody armed activated T cell (BAT) and a cancer cell, to thereby treat cancer in the subject.

IPC Classes  ?

• A61K 35/17 - Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
• A61K 35/13 - Tumour cells, irrespective of tissue of origin
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61P 35/00 - Antineoplastic agents

Abstract

Embodiments relate to a system for predicting thermodynamic phase of a material. The system includes a phase diagram image scanning processing module configured to scan a binary phase diagram for each material to be used as a component of a high-entropy alloy (HEA). The system includes a feature computation processing module configured to generate a primary feature and an adaptive feature. The primary feature is representative of a probability that the HEA will exhibit a solid solution phase and/or an intermetallic phase. The adaptive feature is representative of a factor favoring formation of a desired intermetallic HEA phase. The system includes a prediction module configured to encode the primary feature and/or the adaptive feature with thermodynamic data associated with formation of HEA alloy phases to provide an output representation of the HEA alloy phases for a material under analysis.

IPC Classes  ?

• G16C 20/30 - Prediction of properties of chemical compounds, compositions or mixtures
• G16C 60/00 - Computational materials science, i.e. ICT specially adapted for investigating the physical or chemical properties of materials or phenomena associated with their design, synthesis, processing, characterisation or utilisation
• G16C 20/70 - Machine learning, data mining or chemometrics
• C22C 30/00 - Alloys containing less than 50% by weight of each constituent

Abstract

Systems, methods, and devices are described herein for identifying, monitoring, isolating, or selecting a cell having a predefined characteristic in a mixed population of cells utilizing a combination of any one or more of iDEP, a region of localized field enhancement, a variable frequency electric field, a wide bandwidth amplifier, and/or an imaging apparatus.

IPC Classes  ?

• C12Q 1/04 - Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
• B03C 5/02 - Separators
• G01N 33/569 - Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• B03C 5/00 - Separating dispersed particles from liquids by electrostatic effect

Abstract

A set of target peptides are presented by HLA A*0101, A*0201, A*0301, B*4402, B*2705, B*1402, and B*0702 on the surface of disease cells. They are envisioned to among other things (a) stimulate an immune response to the proliferative disease, e.g., cancer, (b) to function as immunotherapeutics in adoptive T cell therapy or as a vaccine, (c) facilitate antibody recognition of tumor boundaries in surgical pathology samples, (d) act as biomarkers for early detection and/or diagnosis of the disease, and (e) act as targets in the generation antibody-like molecules which recognize the target-peptide/MHC complex.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 35/15 - Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
• A61K 35/17 - Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• G01N 33/574 - Immunoassay; Biospecific binding assay; Materials therefor for cancer
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Abstract

In one aspect, the disclosure relates to compounds useful to regulate, limit, or inhibit the expression of AVIL (advillin), methods of making same, pharmaceutical compositions comprising same, and methods of treating disorders associated with AVIL dysregulation using same. In aspects, the disclosed compounds, compositions and methods are useful for treating disorders or diseases in which the regulation, limitation, or inhibition of the expression of AVIL can be clinically useful, such as, for example, the treatment of cancer. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

IPC Classes  ?

• A61K 31/506 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
• A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/04 - Antineoplastic agents specific for metastasis

Abstract

Compositions and methods are provided that are useful for diagnosing, treating, and monitoring alcohol dependence and disorders, susceptibility to alcohol dependence disorders, as well as drug related dependence and disorders. The methods include treating patients with an antagonist of the serotonin receptor 5-HT3 for such disorders, wherein the patient's serotonin transporter gene SLC6A4 is known to have particular genotypes.

IPC Classes  ?

• A61K 31/4178 - 1,3-Diazoles not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
• G16B 20/00 - ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• C12Q 1/6888 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
• A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin

Abstract

The present application provides compositions and methods for preparing and using “heavy” nucleotide derivatives of thymidine or uridine by replacing the oxygen atom attached to one or more of positions with non-radioactive oxygen-18 (18O), administering it to a subject to target a tumor including incorporation into tumor cell DNA, and then treating the tumor with proton beam therapy to transmutate the 18O to 18F, resulting in a break of the new fluorine-phosphorous bond. This chemical event destabilizes ribose-phosphate DNA back-bone and base pairing thus produce single- and double strand breaks, clusters lesions that can lead to irreparable DNA damage and enhanced tumor cell killing. The atomic, chemical, and physical aspects result in the use of lower radiation doses and significantly alter acute and late morbidity of radiotherapy. Heavy thymidine and heavy uridine derivatives labeled with 18O have been made and tested.

IPC Classes  ?

• C07H 19/073 - Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
• A61N 5/10 - X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
• C07B 59/00 - Introduction of isotopes of elements into organic compounds
• A61K 31/7072 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
• A61P 35/00 - Antineoplastic agents

Abstract

Provided are compositions that can be employed for generating microporous gel systems. In some embodiments, the compositions include at least one sub-population of soft hydrogel microparticles with a Youngs modulus of less than 50 kPa and at least one sub-population of stiff hydrogel microparticles with a Young's modulus of greater than 90 kPa. Also provided are methods for generating the compositions, methods for treating bone and/or cartilage defects in subject using the disclosed compositions, methods for treating osteoarthritis using the disclosed compositions, and methods for providing orthopedic implants to subjects.

IPC Classes  ?

• A61L 27/52 - Hydrogels or hydrocolloids
• A61L 27/54 - Biologically active materials, e.g. therapeutic substances
• A61L 27/56 - Porous or cellular materials

Abstract

Methods and compositions for modulating transforming growth factor-beta (TGFβ) biological activity in a vertebrate subject in need thereof. The methods involve administering to the vertebrate subject an effective amount of a substance capable of modulating activity of LEMD3 in the vertebrate subject to thereby modulate TGFβ biological activity in the vertebrate subject.

IPC Classes  ?

• C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
• A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• A61P 17/00 - Drugs for dermatological disorders
• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

Methods, systems, and computer readable media for utilizing a therapeutic ultrasound device to perform mitral valve decalcification are disclosed. One method includes acquiring, via an ultrasound imaging component, imaging data of a mitral valve in real-time, defining a therapeutic region of interest corresponding to the mitral valve, and utilizing, by a system controller engine, imaging data from the ultrasound imaging component to determine an interval period of minimal mitral annular movement. The method further includes defining a sequence of therapeutic targets within the region of interest of the mitral valve, utilizing the imaging data acquired in real-time by the ultrasound imaging component to provide a therapeutic ultrasound transducer array with a location and depth of an intra-annular focal zone within the mitral valve, and emitting a high intensity focused ultrasound (HIFU) pulse wave from the therapeutic ultrasound transducer array to each of the therapeutic targets of the mitral valve during the determined interval period and in accordance with the defined sequence.

IPC Classes  ?

• A61B 8/08 - Detecting organic movements or changes, e.g. tumours, cysts, swellings
• A61B 34/10 - Computer-aided planning, simulation or modelling of surgical operations

Abstract

A method of operating a finite state machine circuit can be provided by determining if a target sequence of characters included in a string of reference characters occurs within a specified difference distance using states indicated by the finite state machine circuit to indicate a number of character mis-matches between the target sequence of characters and a respective sequence of characters within the string of reference characters.

IPC Classes  ?

• G16B 30/00 - ICT specially adapted for sequence analysis involving nucleotides or amino acids
• G06N 5/04 - Inference or reasoning models
• G06F 16/903 - Querying

Abstract

Provided are nucleotide sequences encoding polypeptides with ribonuclease III activity, wherein the nucleotide sequences have been modified to reduce their regulation by miRNAs. In some embodiments, the nucleotide sequences are at least 50% and as much as 100% identical to SEQ ID NO: 20 or SEQ ID NO: 22, and/or encode polypeptides that are at least 90% percent identical to SEQ ID NO: 23. Also provided are vectors and host cells that include the nucleotide sequences, methods for expressing the nucleotide sequences in cells, tissues, and organs, which in some embodiments can be in the eye of a subject in need thereof, methods for preventing and/or treating development of diseases or disorders and/or for restoring undesirably low DICER1 expression using the nucleotide sequences, and pharmaceutical compositions that have the presently disclosed nucleotide sequences.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• C12N 9/16 - Hydrolases (3.) acting on ester bonds (3.1)
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
• A61P 27/02 - Ophthalmic agents

Abstract

A method, system, and computer-readable medium for providing a real-time estimation of laboratory glycosylated hemoglobin (HbA1c) at one or more intervals. The real-time estimation is conferred as a value of estimated, time variable A1e (eA1c) based on daily continuous glucose monitoring (CGM)-derived time in target range (TIR) (CGM-TIR). The eA1c value is adjusted based on a sole laboratory HbA1c value for an interval preceding an interval corresponding to the eA1c value so as to provide an expected value for a laboratory HbA1c value at the same corresponding interval.

IPC Classes  ?

• A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration, pH-value
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Abstract

Provided are methods for treating a disease, disorder, or condition associated with an acid ceramidase (AC) biological activity. The methods include administering to a subject in need thereof a composition including an AC inhibitor and at least one additional active agent, such as a C6-ceramide nanoliposome (CNL); an inhibitor of a Bcl-2 family protein; a hypomethylating agent; an intensive chemotherapeutic agent such as cytarabine (AraC) and/or daunorubicin; a Hedgehog pathway inhibitor; a targeted agent, such as a FLT2 inhibitor or a EDH1/2 inhibitor; and/or an antibody drug conjugate that targets, for example, CD-33. The composition can include N-[(2S,3R)-1,3-dihydroxyoctadecan-2-yl]2-chloroacetamide (SACLAC) or a pharmaceutically acceptable salt thereof and at least one additional active agent. The disease, disorder, or condition associated with the AC biological activity can be a cancer, such as acute myeloid leukemia (AML).

IPC Classes  ?

• A61K 31/164 - Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
• A61K 31/635 - Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide having a heterocyclic ring, e.g. sulfadiazine
• A61K 31/706 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
• A61K 9/127 - Liposomes
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 35/02 - Antineoplastic agents specific for leukemia